Myopathy induced by epsilon-aminocaproic acid. Case report.
The authors present a case of proximal myopathy secondary to epsilon-aminocaproic acid (EACA) administration. This well recognized entity does not occur immediately after institution of therapy, but follows a delay of several days and a cumulative dose. Its consequences include a spectrum of symptoms from myalgias to severe myopathy with rhabdomyolysis, myoglobinuria, and acute tubular necrosis. A presenting symptom of calf pain in a patient receiving EACA should not automatically imply deep vein thrombosis. Serial creatine phosphokinase measurements are essential in monitoring a patient undergoing EACA therapy, especially after 2 weeks of treatment and a total dose of greater than 500 gm.
D000368:Aged; D000614:Aminocaproates / Q000009:adverse effects*; D015119:Aminocaproic Acid / Q000009:adverse effects*; D001706:Biopsy; D005260:Female; D006801:Humans; D002532:Intracranial Aneurysm / Q000188:drug therapy; D007866:Leg; D009135:Muscular Diseases / Q000139:chemically induced* / Q000473:pathology; D012782:Shoulder
D000614:Aminocaproates; D015119:Aminocaproic Acid